Compare BHM & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | CRVO |
|---|---|---|
| Founded | 2022 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 47.7M |
| IPO Year | N/A | N/A |
| Metric | BHM | CRVO |
|---|---|---|
| Price | $9.48 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $21.50 |
| AVG Volume (30 Days) | 7.3K | ★ 94.1K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 5.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,462,000.00 | $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.95 | N/A |
| 52 Week Low | $8.05 | $1.92 |
| 52 Week High | $14.81 | $16.94 |
| Indicator | BHM | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 32.15 |
| Support Level | $8.60 | $4.54 |
| Resistance Level | $9.40 | $5.65 |
| Average True Range (ATR) | 0.43 | 0.51 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 74.77 | 12.86 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.